Antigen binding protein and its use as addressing product for the treatment of cancer

Patent metadata

Field	Value
Publication number	US-9689862-B2
Application number	US-201214355986-A
Country	US
Kind code	B2
Filing date	Nov 5, 2012
Priority date	Nov 3, 2011
Publication date	Jun 27, 2017
Grant date	Jun 27, 2017

Abstract

The present invention relates to an antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to an antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.

First claim

The invention claimed is:

1. An antigen binding protein, or an antigen binding fragment thereof, wherein the antigen binding protein or fragment:
i) specifically binds to a human protein Axl and
ii) is internalized following its binding to said human protein Axl, and wherein
said antigen binding protein is an antibody, said antibody comprising the three light chain complementarity determining regions CDR-L1, CDR-L2, and CDR-L3 comprising the sequences SEQ ID NOs. 1, 2, and 3, respectively; and the three heavy chain CDRs, CDR-H1, CDR-H2, and CDR-H3 comprising the sequences SEQ ID NOs. 4, 5, and 6, respectively.

2. The antigen binding protein, or an antigen binding fragment thereof, according to claim 1 , wherein the antigen binding protein or fragment induces a reduction of mean fluorescence intensity (MFI) measured by Fluorescence Activated Cell Sorting (FACS) of at least 200.

3. The antigen binding protein, or an antigen binding fragment thereof, according to claim 1 , wherein the antigen binding protein is a monoclonal antibody.

4. The antigen binding protein, or an antigen binding fragment thereof, according to claim 1 , wherein the antigen binding protein or fragment comprises a light chain variable domain selected from the group consisting of:
i) a light chain variable domain of sequence SEQ ID NO. 7 or any sequence exhibiting at least 80% identity with SEQ ID NO.7,
ii) a light chain variable domain of sequence SEQ ID NO. 36 or any sequence exhibiting at least 80% identity with SEQ ID NO. 36; and
iii) a light chain variable domain of sequence SEQ ID NO. 37 to 47 or any sequence exhibiting at least 80% identity with SEQ ID NO. 37 to 47.

5. The antigen binding protein, or an antigen binding fragment thereof, according to claim 1 , wherein the antigen binding protein or fragment comprises a heavy chain variable domain selected from:
i) a heavy chain variable domain of sequence SEQ ID NO. 8 or any sequence exhibiting at least 80% identity with SEQ ID NO.8;
ii) a heavy chain variable domain of sequence SEQ ID NO. 48 or any sequence exhibiting at least 80% identity with SEQ ID NO. 48; or
iii) a heavy chain variable domain of sequence SEQ ID NO. 49 to 68 or any sequence exhibiting at least 80% identity with SEQ ID NO. 49 to 68.

6. The antigen binding protein, or an antigen binding fragment thereof, according to claim 1 , wherein the antigen binding protein or fragment comprises:
i) a light chain variable domain of sequence SEQ ID NO. 7, 36, or 37 to 47, or any sequence exhibiting at least 80% identity with SEQ ID NO.7, 36, or 37 to 47; and
ii) a heavy chain variable domain of sequence SEQ ID NO. 8, 48, or 49 to 68, or any sequence exhibiting at least 80% identity with SEQ ID NO.8, 48, or 49 to 68.

7. The antigen binding protein according to claim 1 , wherein the antigen binding protein consists of the monoclonal antibody 1613F12 produced by the hybridoma I-4505 deposited at the CNCM, Institut Pasteur, France, on the 28 Jul. 2011, or an antigen binding fragment thereof.

8. The murine hybridoma I-4505 deposited at the CNCM, Institut Pasteur, France, on the 28 Jul. 2011.

9. An immunoconjugate, comprising the antigen binding protein, or an antigen binding fragment thereof, according to claim 1 conjugated to a cytotoxic agent.

10. A pharmaceutical composition, comprising the immunoconjugate of claim 9 and at least an excipient and/or a pharmaceutical acceptable vehicle.

11. The antigen binding protein, or an antigen binding fragment thereof, according to claim 1 , wherein the human protein Axl of claim 1 has the sequence of SEQ ID NOS. 29 or 30, or of natural variant sequence thereof.

12. The antigen binding protein, or an antigen binding fragment thereof, according to claim 1 , wherein the antigen binding protein or fragment specifically binds to an epitope localized into the human protein Axl extracellular domain having the sequence of SEQ ID NO. 31 or 32, or a natural variant sequence thereof.

13. The antigen binding protein, or an antigen binding fragment thereof, according to claim 1 , wherein the antigen binding protein or fragment comprises a light chain variable domain of sequence SEQ ID NO. 47 and a heavy chain variable domain of sequence SEQ ID NO 68.

14. An immunoconjugate, comprising the antigen binding protein, or an antigen binding fragment thereof, according to claim 13 conjugated to a cytotoxic agent.

15. A pharmaceutical composition, comprising the immunoconjugate of claim 14 and at least an excipient and/or a pharmaceutical acceptable vehicle.

Assignees

• Pf Medicament
• Peirre Fabre Medicament

Inventors

• Beau-Larvor Charlotte
• Goetsch Liliane
• Boute Nicolas

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• A61K47/6851

  the antibody targeting a determinant of a tumour cell · CPC title

• A61K47/6843

  the antibody targeting a material from animals or humans · CPC title